19-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
7-Nov-2025 8:00 AM CST - Business Wire Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
5-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approximately two months ahead of schedule and continue to see strong momentum across ECLIPSE 2 and 3, positioning us well fo
22-Oct-2025 3:05 PM CST - Business Wire Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section o
25-Aug-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archi
6-Aug-2025 3:05 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune system to transform lives, said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. The initiation of our Phase 1 study of PRO-XTEN dual-masked VIR-5525 positions us to potentia
22-Jul-2025 3:05 PM CST - Business Wire Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vi
28-May-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be ar
20-May-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Inv
19-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
7-Nov-2025 8:00 AM CST - Business Wire Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
5-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approximately two months ahead of schedule and continue to see strong momentum across ECLIPSE 2 and 3, positioning us well fo
22-Oct-2025 3:05 PM CST - Business Wire Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section o
25-Aug-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archi
6-Aug-2025 3:05 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune system to transform lives, said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. The initiation of our Phase 1 study of PRO-XTEN dual-masked VIR-5525 positions us to potentia
22-Jul-2025 3:05 PM CST - Business Wire Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vi
28-May-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be ar
20-May-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Inv
